| Ytd | 1.72% | |
| 1y | 18.95% |
| Open | 2.96 | Prev Close | 2.96 | Low | 2.91 | High | 3.08 | Mkt Cap | 119.17M |
| Vol | 223.09K | Avg Vol | 224.66K | EPS | -3.03 | P/E | N/A | Forward P/E | -2.64 |
| Beta | 0.23 | Short Ratio | 19.81 | Inst. Own | 53.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 3.86 | 200-d Avg | 3.68 | 1yr Est | 34.75 |
OKUR News
BOULDER, Colo., Aug. 31, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinic
-- Executing IND-enabling activities for next-generation PI3Kα pan-mutant selective candidates OKI-
OnKure Therapeutics NASDAQ: OKUR used a scientific webcast to outline its strategy for developing mu
BOULDER, Colo., July 02, 2026 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinic
Gainers Catheter Precision (AMEX:VTAK) shares rose 78.2% to $1.55 during Monday's after-market
-- Announced nomination of OKI-355, a next-generation PI3Kα pan-mutant selective inhibitor candidate
-- Financing led by Access Biotechnology with participation from new and existing investors -- Finan
Top analysts updated ratings for MU, EPAM, WLTH, OKUR, BLDR, DMRC, JBIO, CRCL. See changes and ratin
-- Data from the ongoing PIKture-01 trial is expected to be announced in March 2026 ; continued enro
Shares of OnKure Therapeutics, Inc. (NASDAQ: OKUR - Get Free Report) have been assigned an average r
-- First patients dosed in triplet expansion arms of the PIKture-01 trial evaluating OKI-219 in comb
BOULDER, Colo., Nov. 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clinic
-- PIKture-01, a phase 1 clinical trial assessing OKI-219 in patients with advanced solid tumors, in
-- Continued progress in the PIKture-01 trial; on track to report additional data in the second half
— PIKture-01 trial update including additional PK data, mature single agent and initial combination
BOULDER, Colo., March 04, 2025 (GLOBE NEWSWIRE) -- OnKure Therapeutics, Inc. (Nasdaq: OKUR), a clini
-- OKI-219 is well-tolerated across all doses, and no dose interruptions, delays, reductions, or dis
Investor call to review preliminary data from the PIKture-01 trial is now planned for Tuesday, Decem
OnKure to host a conference call to review key data presented at SABCS and provide a general corpora
Initial OnKure Therapeutics, Inc. data from the phase 1 PIKture-01 study, using OKI-219 for the trea
-- OnKure is focused on advancing a pipeline of candidates targeting oncogenic mutations in phosphoi